REVIEW ARTICLE
Are mast cells important in diabetes?
1
Department of Neurology, Carver College of Medicine, University of Iowa, Iowa, USA
2
Department of Pharmacology, University of Perugia, Perugia, Italy
3
Policlinico Gemelli, Rome, Italy
4
Villa Serena Hospital, Città Sant’Angelo, Italy
5
Postgraduate Medical School, Università G. d’Annunzio, Chieti, Italy
Submission date: 2016-04-18
Final revision date: 2016-05-30
Acceptance date: 2016-06-09
Publication date: 2016-11-25
Corresponding author
Pio Conti
Postgraduate Medical School Università G. d’Annunzio, Italy viale Unità d’Italia 66100 Chieti, Italy
Postgraduate Medical School Università G. d’Annunzio, Italy viale Unità d’Italia 66100 Chieti, Italy
Pol J Pathol 2016;67(3):199-206
KEYWORDS
TOPICS
ABSTRACT
Diabetes is a metabolic disorder characterized by hyperglycemia and associated with microvascular and macrovascular syndromes mediated by mast cells. Mast cells are activated through cross-linking of their surface high affinity receptors for IgE (FcRI) or other antigens, leading to degranulation and release of stored inflammatory mediators, and cytokines/chemokines without degranulation. Mast cells are implicated in innate and acquired immunity, inflammation and metabolic disorders such as diabetes. Histamine and tryptase genes in mast cells are overexpressed in pancreatic tissue of type 2 diabetes mellitus (T2DM) patients. Histamine is a classic inflammatory mediator generated by activated receptors of mast cells from the histamine-forming enzyme histidine decarboxylase (HDC), which can be activated by two inflammatory chemokines, RANTES and MPC1, when injected intramuscularly or intradermally in mice. This activation is inhibited in genetically mast cell-deficient W/Wv mice, which show higher insulin sensitivity and glucose tolerance. This study contributes to understanding the mechanism by which mast cells profoundly affect diabetes, and their manipulation could represent a new therapeutic strategy. However, further studies are needed to clarify the role of mast cells in inflammation and metabolic disorders such as diabetes.
REFERENCES (78)
1.
Conti P, Youinou P, Theoharides TC. Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32). Autoimmun Rev 2007; 6: 131-137.
2.
Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15: 644-648.
3.
Kalish RS, Askenase PW. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity. J Allergy Clin Immunol 1999; 103: 192-199.
4.
Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol 2015; 15: 271-282.
5.
Oki S, Miyake S. Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases. Allergol Int 2007; 56: 7-14.
6.
Marcinkiewicz J. Cell-mediated immunity: role of IL-3 and IL-6 in the regulation of contact sensitivity reaction. Folia Histochem Cytobiol 1990; 28: 107-119.
7.
Clardy SL, Lennon VA, Dalmau J, et al. Childhood onset of stiff-man syndrome. JAMA Neurol 2013; 70: 1531-1536.
8.
Craighead JE. Current views on the etiology of insulin-dependent diabetes mellitus. N Engl J Med 1978; 299: 1439-1445.
9.
Tahergorabi Z, Khazaei M. Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med 2012; 3: 827-838.
10.
Di Gialleonardo V, de Vries EF, Di Girolamo M, et al. Imaging of -cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus. Endocr Rev 2012; 33: 892-919.
11.
Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci 2012; 118: 311-316.
12.
Gu Y, Yang DK, Spinas E, et al. Role of TNF in mast cell neuroinflammation and pain. J Biol Regul Homeost Agents 2015; 29: 787-791.
13.
Venkatesha SH, Dudics S, Weingartner E, et al. Altered Th17/Treg balance and dysregulated IL-1 response influence susceptibility/resistance to experimental autoimmune arthritis. Int J Immunopathol Pharmacol 2015; 28: 318-328.
14.
Zheng Z, Huang H, Yu Y, Liang J. Overexpression of FgI2 deteriorates the heart function of experimental autoimmune myocarditis rats. Eur J Inflamm 2015; 13: 66-71.
15.
Sannegowda KM, Venkatesha SH, Moudgil KD. Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage. Int J Immunopathol Pharmacol 2015; 28: 521-531.
16.
Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354: 24-31.
17.
Padgett LE, Broniowska KA, Hansen PA, et al. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci 2013; 1281: 16-35.
18.
Hober D, Sauter P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat Rev Endocrinol 2010; 6: 279-289.
19.
Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus. Inflammation 2013; 36: 364-371.
20.
Conti P, Pang X, Boucher W, et al. Impact of Rantes and MCP-1 chemokines on in vivo basophilic cell recruitment in rat skin injection model and their role in modifying the protein and mRNA levels for histidine decarboxylase. Blood 1997; 89: 4120-4127.
21.
Licari A, De Amici M, Nigrisoli S, et al. Tryptase and histamine may support oral food challenge in the diagnosis of allergy. J Biol Regul Homeost Agents 2015; 29: 1-7.
22.
Theoharides TC, Petra AI, Taracanova A, et al. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther 2015; 354: 24-31.
23.
Eskandari N, Tashrifi F, Bastan R, et al. Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells. Int J Immunopathol Pharmacol 2016; pii: 0394632015626150.
24.
Toniato E, Spinas E, Saggini A, et al. Immunomodulatory effects of vitamin d on skin inflammation. J Biol Regul Homeost Agents 2015; 29: 563-567.
25.
Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells 2014; 37: 365-371.
26.
Bonnefoy JY, Gauchat JF, Life P, et al. Pairs of surface molecules involved in human IgE regulation: CD23-CD21 and CD40-CD40L. Eur Respir J Suppl 1996; 22: 63-66.
27.
Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood 2000; 96: 4028-4038.
28.
Petra AI, Panagiotidou S, Stewart JM, et al. Spectrum of mast cell activation disorders. Expert Rev Clin Immunol 2014; 10: 729-739.
29.
Sykora KW, Tomeczkowski J, Reiter A. C-kit receptors in childhood malignant lymphoblastic cells. Leuk Lymphoma 1997; 25: 201-216.
30.
Theoharides TC, Kempuraj D, Tagen M, et al. Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev 2007; 217: 65-78.
31.
Tan SL, Parker PJ. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochem J 2003; 376: 545-552.
32.
Zhang J, Shi GP. Mast cells and metabolic syndrome. Biochim Biophys Acta 2012; 1822: 14-20.
33.
Walz P, Ladowski JS, Hines A. Distal revascularization and interval ligation (DRIL) procedure for the treatment of ischemic steal syndrome after arm arteriovenous fistula. Ann Vasc Surg 2007; 21: 468-473.
34.
Simmons K, Michels AW. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am 2014; 40: 797-811.
35.
Shi MA, Shi GP. Different roles of mast cells in obesity and diabetes: lessons from experimental animals and humans. Front Immunol 2012; 3: 7.
36.
Chen GT, Han N, Li GF, et al. TNF- mutation affects the gene expression profile of patients with multiple trauma. Eur J Inflamm 2015; 13: 109-116.
37.
Tharp MD. The interaction between mast cells and endothelial cells. J Invest Dermatol 1989; 93: 107-112.
38.
Papaccio G. Insulitis and islet microvasculature in type 1 diabetes. Histol Histopathol 1993; 8: 751-759.
39.
Shinomiya M, Nadano S, Shinomiya H, Onji M. In situ characterization of dendritic cells occurring in the islets of nonobese diabetic mice during the development of insulitis. Pancreas 2000; 20: 290-296.
40.
Möller E, Valugerdi MA, Ridderstad A. Specific and non-specific autoreactive immunity. J Autoimmun 1992; 5: 37-44.
41.
Li CR, Baaten BJ, Bradley LM. Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. J Mol Cell Biol 2012; 4: 38-47.
42.
Milovanovic M, Volarevic V, Radosavljevic G. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52: 89-99.
43.
Starska K, Brzezińska-Błaszczyk E. The role of stromal mast cells in the modification of CD4+CD25+Foxpł regulatory T cells, Th17 lymphocytes and cytotoxic lymphocytes Tc1 in the development and progression of tumor. Postepy Hig Med Dosw (Online) 2010; 64: 408-416.
44.
Sia C, Hänninen A. Functional alterations of proinflammatory monocytes by T regulatory cells: implications for the prevention and reversal of type 1 diabetes. Rev Diabet Stud 2010; 7: 6-14.
45.
Noble JA, Johnson J, Lane JA, Valdes AM. HLA class II genotyping of African American type 1 diabetic patients reveals associations unique to African haplotypes. Diabetes 2013; 62: 3292-3299.
46.
Lukic ML, Mensah-Brown E, Wei X, et al. Lack of the mediators of innate immunity attenuate the development of autoimmune diabetes in mice. J Autoimmun 2003; 21: 239-246.
47.
Conti P, Reale M, Barbacane RC, et al. Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell-deficient W/Wv mice. FASEB J 1998; 12: 1693-1700.
48.
Hattersley AT, Thorens B. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion. N Engl J Med 2015; 373: 974-976.
49.
Ikeda T. The pathogenesis of vitreoretinal diseases from the standpoint of molecular biology. Nippon Ganka Gakkai Zasshi 2003; 107: 785-812.
50.
Lee M, Calabresi L, Chiesa G, et al. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2002; 22: 1475-1481.
51.
Conti P, Shaik-Dasthagirisaheb YB. Mast cell serotonin immunoregulatory effects impacting on neuronal function: implications for neurodegenerative and psychiatric disorders. Neurotox Res 2015; 28: 147-153.
52.
Hübner MP, Larson D, Torrero MN. Anti-FcR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice. Clin Immunol 2011; 141: 205-217.
53.
Shi GP, Bot I, Kovanen PT. Mast cells in human and experimental cardiometabolic diseases. Nat Rev Cardiol 2015; 12: 643-658.
54.
Woolley DE. The mast cell in inflammatory arthritis. N Engl J Med 2003; 348: 1709-1711.
55.
Qin L, Zhao D, Xu J, et al. The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood 2013; 121: 2154-2164.
56.
Au RY, Al-Talib TK, Au AY, et al. Avocado soybean unsaponifiables (ASU) suppress TNF-αlpha, IL-1beta, COX-2, iNOS gene expression, and prostaglandin E2 and nitric oxide production in articular chondrocytes and monocyte/macrophages. Osteoarthritis Cartilage 2007; 15: 1249-1255.
57.
Kohlgruber A, Lynch L. Adipose tissue inflammation in the pathogenesis of type 2 diabetes. Curr Diab Rep 2015; 15: 92.
58.
Antonelli A, Ferrari SM, Giuggioli D, et al. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5: 586-600.
59.
Tonnel AB, Gosset P, Molet S, et al. Interactions between endothelial cells and effector cells in allergic inflammation. Ann N Y Acad Sci 1996; 796: 9-20.
60.
Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-αlpha function. Nature 1997; 389: 610-614.
61.
Reber LL, Sibilano R, Mukai K, Galli SJ. Potential effector and immunoregulatory functions of mast cells in mucosal immunity. Mucosal Immunol 2015; 8: 444-463.
62.
Xu Y, Chen G. Mast cell and autoimmune diseases. Mediators Inflamm 2015; 2015: 246126.
63.
Wesolowski J, Paumet F. The impact of bacterial infection on mast cell degranulation. Immunol Res 2011; 51: 215-226.
64.
Rodewald HR, Feyerabend TB. Widespread immunological functions of mast cells: fact or fiction? Immunity 2012; 37: 13-24.
65.
Ryba-Stanisławowska M, Stanisławowski M, Myśliwska J. Effector and regulatory T cell subsets in diabetes-associated inflammation. Is there a connection with ST2/IL-33 axis? Perspective. Autoimmunity 2014; 47: 361-371.
66.
Manti S, Chimenz R, Salpietro A, et al. Atopic dermatitis: expression of immunological imbalance. J Biol Regul Homeost Agents 2015; 29 (2 Suppl 1): 13-17.
67.
Shin JS, Abraham SN. Co-option of endocytic functions of cellular caveolae by pathogens. Immunology 2001; 102: 2-7.
68.
Sandig H, Bulfone-Paus S. TLR signaling in mast cells: common and unique features. Front Immunol 2012; 3: 185.
69.
Avila M, Gonzalez-Espinosa C. Signaling through Toll-like receptor 4 and mast cell-dependent innate immunity responses. IUBMB Life 2011; 63: 873-880.
70.
Abella V, Scotece M, Conde J, et al. The novel adipokine progranulin counteracts IL-1 and TLR4-driven inflammatory response in human and murine chondrocytes via TNFR1. Sci Rep 2016; 6: 20356.
71.
Dvorak AM. New aspects of mast cell biology. Int Arch Allergy Immunol 1997; 114: 1-9.
72.
Garozzo MT, Cuppari C, Filippelli M, et al. Relation of body mass index with ige levels, allergic sensitization and lung function in asthmatic children: our experience and revision of literature. J Biol Regul Homeost Agents 2015; 29: 89-95.
73.
Masaki T, Yoshimatsu H. Neuronal histamine and its receptors in obesity and diabetes. Curr Diabetes Rev 2007; 3: 212-216.
74.
Aronin N, Leeman SE, Clements RS Jr. Diminished flare response in neuropathic diabetic patients. Comparison of effects of substance P, histamine, and capsaicin. Diabetes 1987; 36: 1139-1143.
75.
Sismanopoulos N, Delivanis DA, Alysandratos KD, et al. Mast cells in allergic and inflammatory diseases. Curr Pharm Des 2012; 18: 2261-2277.
76.
Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol 2004; 25: 235-241.
77.
Li Z, Zhou J, Zhu D, et al. Role of endogenous TNF- in cardiomyocyte apoptosis induced by bacteria lipoprotein and the protective effect of IL-10. Eur J Inflamm 2015; 13: 117-125.
78.
Zhang C, Liu X, Zhan H, Chen D. Role of dexmedetomide in IL-4 and IFN- expression in rats with multiple organ dysfunction syndrome induced by postpartum bleeding. Eur J Inflamm 2015; 13: 164-172.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
